drugset / Trial / NCT06943755
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RandomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Timeline
- Start
- 2025-07-21
- Primary completion
- 2029-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Everolimus | Small molecule | — | Oral |
| Subject | Zanzalintinib | Small molecule | — | Oral |